Recent News

SciFluor News

SciFluor Life Sciences Awarded U.S. Patent for Integrin αvβ3 Inhibitors Designed for the Topical Treatment of Retinal Disease
read more >

SciFluor Presents Update on Novel KCNQ2/3 activator at Epilepsy Pipeline Conference
read more >

SciFluor Life Sciences Presents New Preclinical Data Highlighting Lead Program as a More Potent and Selective Treatment for Partial-Onset Seizure
read more >


SciFluor Life Sciences is a drug discovery company applying expertise in fluorine chemistry to create a portfolio of differentiated best-in-class therapeutics.

SciFluor Life Sciences, LLC is a drug discovery and development company harnessing the transformational power of fluorine to create innovative new medicines.  Combining our scientists' knowledge and experience in drug discovery and development with the unique pharmacologic advantages afforded by the strategic incorporation of fluorine in small molecule drugs, SciFluor is creating drug candidates with improved pharmacological profiles that provide important benefits over existing therapies such as improved safety, efficacy, more convenient dosing and better patient compliance. The company creates new chemical entities (NCEs) directed towards precedented biological targets. This approach has resulted in the generation of a pipeline of patent-protected and differentiated small molecule drugs across a range of therapeutic indications including ophthalmic disease, CNS disorders, and inflammation. We are advancing selected development candidates into clinical studies with the aim of partnering at an optimal time.

SciFluor is actively seeking industry partners to drive the development and commercialization of innovative new medicines that address unmet medical needs.

SciFluor was established in 2011 by Harvard University and Allied Minds.